New quadruple immunotherapy attack on childhood cancer

NCT ID NCT05754684

Recruiting now Disease control Sponsor: Hong Kong Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests a combination of four immune-based treatments for children whose neuroblastoma has returned or not responded to standard care. The therapy includes natural killer cells from a relative, two antibodies (dinutuximab beta and naxitamab), immune-boosting cytokines, and a drug called spironolactone. The goal is to see if this powerful mix can shrink tumors and improve survival in 29 young patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Natural killer cells, dinutuximab beta, interleukin-2, GM-CSF, spironolactone, and naxitamab
What this could lead to: If it works, this could offer a new treatment option for children with hard-to-treat neuroblastoma that has come back or not responded to standard therapy.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The combination of multiple immune therapies may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA RECURRENT

Contacts and locations

Locations

Hong Kong Children's Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.